Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.7%

2 terminated out of 35 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

20%

7 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed with results

Key Signals

5 with results90% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (11)
Early P 1 (1)
P 1 (3)
P 2 (5)
P 3 (5)
P 4 (2)

Trial Status

Completed18
Recruiting7
Withdrawn3
Unknown3
Terminated2
Not Yet Recruiting1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT07338773Phase 4Recruiting

Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trial

NCT04714411CompletedPrimary

Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis

NCT06526884Not ApplicableActive Not Recruiting

Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)

NCT05172089Recruiting

Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence

NCT05948592Phase 2CompletedPrimary

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

NCT05369052Phase 3RecruitingPrimary

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

NCT04440839Not ApplicableCompleted

Implementation of Telemedicine for Patient With Lower Extremity Wounds

NCT06667752Not ApplicableRecruiting

Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer

NCT05613985Not ApplicableRecruitingPrimary

PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers

NCT07040488RecruitingPrimary

Study of Infrared Thermography in Diabetic Foot in Guadeloupe

NCT04081792Not ApplicableCompletedPrimary

Optimal Antibiotics for Operated Diabetic Foot Infections

NCT04450693Phase 3CompletedPrimary

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

NCT06020235Phase 2Not Yet RecruitingPrimary

Nu-3 Gel for Infected Diabetic Foot Ulcers

NCT05610865Phase 1Recruiting

Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers

NCT03964571Not ApplicableCompletedPrimary

Human and Bacterial Protease Activity As Prognostic Tool of Foot Infections in Diabetic Patients

NCT05174806Phase 2CompletedPrimary

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

NCT05616351CompletedPrimary

Antibiotic Therapy in Infections of the Diabetic Foot Syndrome

NCT04176120Phase 3CompletedPrimary

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

NCT05564728Completed

Diabetes Footcare Companion App for Patients and Carers

NCT05243810Not ApplicableCompleted

EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers

Scroll to load more

Research Network

Activity Timeline